A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of Recurrence
Latest Information Update: 26 May 2025
At a glance
- Drugs Mitomycin (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms UTOPIA
- Sponsors UroGen Pharma
Most Recent Events
- 12 May 2025 According to a UroGen Pharma media release, enrollment is expected to be completed by mid-2025.
- 09 Apr 2025 Planned number of patients changed from 87 to 92.
- 09 Apr 2025 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.